Scarica l'app Stockscreener
17.18
5.66%
-1.03
Dopo l'orario di chiusura:
17.18
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché AVTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$18.21
Aprire:
$17.92
Volume 24 ore:
913.73K
Relative Volume:
0.76
Capitalizzazione di mercato:
$921.36M
Reddito:
$59,000
Utile/perdita netta:
$-84.74M
Rapporto P/E:
-2.9508
EPS:
-5.8222
Flusso di cassa netto:
$-59.69M
1 W Prestazione:
-9.58%
1M Prestazione:
-13.10%
6M Prestazione:
+1.51%
1 anno Prestazione:
+55.90%
Intervallo 1D:
$17.15
$18.05
Intervallo di 1 settimana:
$17.15
$20.49
Portata 52W:
$9.54
$24.27
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Nome
Avalo Therapeutics Inc
Settore
Industria
Telefono
410-522-8707
Indirizzo
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
17.18 | 976.60M | 59,000 | -84.74M | -59.69M | -5.8222 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | Wolfe Research | Outperform |
| 2026-04-06 | Iniziato | Citizens | Mkt Outperform |
| 2026-02-02 | Iniziato | Guggenheim | Buy |
| 2025-12-18 | Iniziato | Mizuho | Outperform |
| 2025-09-17 | Reiterato | H.C. Wainwright | Buy |
| 2025-09-05 | Iniziato | TD Cowen | Buy |
| 2025-08-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2025-03-25 | Iniziato | Jefferies | Buy |
| 2025-03-25 | Iniziato | Stifel | Buy |
| 2025-02-28 | Iniziato | Piper Sandler | Overweight |
| 2025-02-21 | Iniziato | Wedbush | Outperform |
| 2024-12-19 | Iniziato | BTIG Research | Buy |
| 2024-10-24 | Iniziato | H.C. Wainwright | Neutral |
| 2024-04-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-09-24 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Avalo Therapeutics Inc Borsa (AVTX) Ultime notizie
Avalo Therapeutics at Cantor conference: building around il-1 beta By Investing.com - Investing.com Canada
(AVTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Avalo Therapeutics Inc. (AVTX) Peer Comparison – Compare with Others - Value Research
Avalo Therapeutics Inc. (AVTX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise (NASDAQ:AVTX) - Seeking Alpha
Avalo Therapeutics Inc. (AVTX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Avalo Therapeutics to Participate in Upcoming Investor Conferences - finance.yahoo.com
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com South Africa
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock - Investing.com
Avalo Therapeutics CFO Sullivan sells over $1.4m in stock By Investing.com - Investing.com Canada
Avalo Therapeutics CFO Sullivan sells over $1.4m in stock - Investing.com
Avalo Therapeutics (AVTX) CMO trades shares under 10b5-1 plan - Stock Titan
Avalo Therapeutics Inc. (AVTX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
How Avalo Therapeutics Inc. (AVTX) Affects Rotational Strategy Timing - Stock Traders Daily
Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares By Investing.com - Investing.com Nigeria
Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares - Investing.com India
Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com - Investing.com Nigeria
AVTX | Avalo Therapeutics, Inc. Common FinancialsRevenue Breakdown - quiverquant.com
Avalo Therapeutics, Inc. Revenue Breakdown – NASDAQ:AVTX - TradingView
Deep Track Capital, LP Expands Avalo Therapeutics Inc (AVTX) Sta - GuruFocus
Avalo (AVTX) Q2 2026 Earnings: The EPS Result Is Below Expectation in the Latest Session; Post-Report: Shares Move 5.28% UpRevenue Growth Outlook - vinanet.vn
Avalo Therapeutics CMO Mittie Doyle Executes Stock Option and Sells 1,000 Shares Under 10b5-1 Plan - Kalkine Media
Avalo Therapeutics (AVTX) CMO sells 1,000 shares in plan - Stock Titan
Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing - marketscreener.com
Avalo Therapeutics (AVTX) CFO sells 72K shares in 10b5-1 trades - Stock Titan
Avalo (AVTX) Financial Update: Profit Per Share Falls Below Its Benchmark in Latest Trading; Post-Report - vinanet.vn
Avalo Therapeutics CFO Christopher Ryan Sullivan Executes Stock Options and Sells Shares Over Two Days - Kalkine Media
Avalo Therapeutics (NASDAQ: AVTX) insider lines up new stock sale after $74K August trade - Stock Titan
Avalo Therapeutics (AVTX) insider lines up $98.7K stock sale - Stock Titan
Avalo Therapeutics, Inc. SEC Filing (Aug 17, 2026) - Stock Titan
Avalo Therapeutics (NASDAQ: AVTX) insider to sell shares - Stock Titan
AVTX Q2 2026 Earnings: Wider-than-Expected Loss of -$0.83 Per Share Highlights Clinical-Stage BurnRevenue Growth Report - Vinanet
Wall Street Zen Upgrades Avalo Therapeutics (NASDAQ:AVTX) to Hold - marketbeat.com
Why Did AVTX Stock Surge 45% In Pre-Market Today? - Stocktwits
Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock By Investing.com - Investing.com Australia
Avalo Therapeutics CSO Jennifer Riley sells $52,012 in stock By Investing.com - Investing.com Canada
Avalo Therapeutics CSO Jennifer Riley sells $52,012 in stock - Investing.com
Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock - Investing.com
AVTX Surges Over 50% After Hours as Skin Disease Drug Shows Desired Clinical Results - Stocktwits
Avalo Therapeutics Stock Price Forecast. Should You Buy AVTX? - StockInvest.us
Avalo Therapeutics (AVTX): Nantahala Capital discloses 3.54% ownership stake - Stock Titan
Caligan Partners (NASDAQ: AVTX) reports 5.9% Avalo Therapeutics ownership on amended 13G - Stock Titan
RA Capital discloses 3.48M-share Avalo Therapeutics (AVTX) position in latest filing - Stock Titan
Avalo Therapeutics (AVTX): BVF group discloses 5.3% beneficial ownership stake - Stock Titan
Avalo Therapeutics (AVTX) sees T. Rowe Price report 3,670-share holding - Stock Titan
Avalo Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | C6K0 | US05338F3064 - marketscreener.com
Avoro Capital and Behzad Aghazadeh report 4.44% AVTX stake in 13G/A filing - Stock Titan
Deep Track Capital (AVTX) discloses 3.61M-share, 6.87% stake in Avalo - Stock Titan
Sei Investments Co. Invests $849,000 in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Avalo Therapeutics (AVTX) sees 5.5% stake reported by Affinity Asset Advisors and Michael Cho - Stock Titan
Avalo Therapeutics Inc Azioni (AVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):